Advances in paclitaxel combinations for treating cervical cancer

References

• Torre LA, Bray F, Siegel RL, et al.. Global cancer statistics, 2012. CA. Cancer J Clinicians. 2016;65(2):87–108.
   Web of Science ®Google Scholar
• Pimple S, Mishra G, Shastri S. Global strategies for cervical cancer prevention. Curr Opin Obstet Gynecol. 2016 Feb;28(1):4–10. . PubMed PMID: 26642063; Eng.
   PubMed Web of Science ®Google Scholar
• Barra F, Leone Roberti Maggiore U, Bogani G, et al. New prophylactics human papilloma virus (HPV) vaccines against cervical cancer. J Obstet Gynaecol. 2019 Jan;39(1):1-10.
   Google Scholar
• Matsuo K, Machida H, Mandelbaum RS, et al. Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol. [Cited 2018 Oct 026];152(2019):87–93.
   PubMedGoogle Scholar
• Liontos M, Kyriazoglou A, Dimitriadis I, et al. Systemic therapy in cervical cancer: 30 years in review. Crit Rev Oncol Hematol. 2019 May;137:9–17. PubMed PMID: 31014518.
   PubMed Web of Science ®Google Scholar
• Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy com- pared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–1143.
   PubMed Web of Science ®Google Scholar
• Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemo- therapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–1153.
   PubMed Web of Science ®Google Scholar
• Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–1161.
   PubMed Web of Science ®Google Scholar
• Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cis- platin versus hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study. J Clin Oncol. 1999;17:1339–1348.
   PubMed Web of Science ®Google Scholar
• Peters III WA, Liu PY, II RJ B, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–1613.
   PubMed Web of Science ®Google Scholar
• NIH News Advisory. NCI issues clinical announcement on cervical cancer: chemotherapy plus radiation improves survival. Embargoed for release. Annals of Human Genetics. 1999;63:101–124. Monday, February 22. 10 a.m. EST
   Google Scholar
• Tewari KS. Novel therapies for advanced cervical cancer. In: Birrer M, Ceppi L, editors. Translational advances in gynecologic cancers. Academic Press; 2017
   Google Scholar
• Rojas-Espaillat LA, Rose PG. Management of locally advanced cervical cancer. Curr Opin Oncol. 2005;17:485–492.
   PubMed Web of Science ®Google Scholar
• Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004 Aug 1;22(15):3113–3119. PubMed PMID: 15284262.
   PubMed Web of Science ®Google Scholar
• Lapresa M, Parma G, Portuesi R, et al. Neoadjuvant chemotherapy in cervical cancer: an update. Expert Rev Anticancer Ther. 2015;15(10):1171–1181. . PubMed PMID: 26402247.
   PubMed Web of Science ®Google Scholar
• Roque DR, Wysham WZ, Soper JT. The surgical management of cervical cancer: an overview and literature review. Obstet Gynecol Surv. 2014 Jul;69(7):426–441. PubMed PMID: 25112591.
   PubMed Web of Science ®Google Scholar
• Sofias AM, Dunne M, Storm G, et al. The battle of “nano” paclitaxel. Adv Drug Deliv Rev. 2017 Dec 1;122:20–30. Epub 2017 Feb 28.
   PubMed Web of Science ®Google Scholar
• Preetha A, Huilgol N, Banerjee R. Effect of fluidizing agents on paclitaxel penetration in cervical cancerous monolayer membranes. J Membr Biol. 2007 Oct;219(1–3):83–91. PubMed PMID: 17712507.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs [review article]. Nat Rev Cancer. 2004 Apr 01;4:253.
   PubMed Web of Science ®Google Scholar
• Alqahtani FY, Aleanizy FS, El Tahir E, et al. Paclitaxel. Profiles Drug Subst Excip Relat Methodol. 2019:44:205–238. PubMed PMID: 31029218.
   PubMedGoogle Scholar
• Ganguly A, Yang H, Cabral F. Paclitaxel-dependent cell lines reveal a novel drug activity. Mol Cancer Ther. 2010 Nov;9(11):2914–2923. . PubMed PMID: 20978163; PubMed Central PMCID: PMCPMC2978777.
   PubMed Web of Science ®Google Scholar
• Tew KD, Paclitaxel; xPharm: the comprehensive pharmacology reference, 2007, 1–5
   Google Scholar
• Zhao L, Feng SS. Effects of lipid chain unsaturation and headgroup type on molecular interactions between paclitaxel and phospholipid within model biomembrane. J Colloid Interface Sci. 2005 May 1;285(1):326–335. . PubMed PMID: 15797430.
   PubMed Web of Science ®Google Scholar
• Crosasso P, Ceruti M, Brusa P, et al. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release. 2000 Jan 3;63(1–2):19–30. PubMed PMID: 10640577.
   PubMed Web of Science ®Google Scholar
• Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release. 2002 Oct 4;83(2):273–286. PubMed PMID: 12363453.
   PubMed Web of Science ®Google Scholar
• Ruan G, Feng SS. Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel. Biomaterials. 2003 Dec;24(27):5037–5044. PubMed PMID: 14559017.
   PubMed Web of Science ®Google Scholar
• Ruel-Gariepy E, Shive M, Bichara A, et al. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Eur J Pharm Biopharm. 2004 Jan;57(1):53–63. PubMed PMID: 14729080.
   PubMed Web of Science ®Google Scholar
• Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001 May 8;103(18):2289–2295. PubMed PMID: 11342479.
   PubMed Web of Science ®Google Scholar
• Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO Clinical practice guidelines. Ann Oncol. 2017;28(suppl 4):iv72–iv83.
   PubMedGoogle Scholar
• Park DC, Kim JH, Lew YO, et al. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol. 2004 Jan;92(1):59–63. PubMed PMID: 14751139.
   PubMed Web of Science ®Google Scholar
• Varan G, Benito JM, Mellet CO, et al. Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery. Beilstein J Nanotechnol. 2017;8:1457–1468. PubMed PMID: 28900599; PubMed Central PMCID: PMCPMC5530618.
   PubMed Web of Science ®Google Scholar
• Bilensoy E, Gurkaynak O, Ertan M, et al. Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J Pharm Sci. 2008 Apr;97(4):1519–1529. PubMed PMID: 17705171.
   PubMed Web of Science ®Google Scholar
• Vallejo CT, Machiavelli MR, Perez JE, et al. Docetaxel as neoadjuvant chemotherapy in patients with advanced cervical carcinoma. Am J Clin Oncol. 2003;26:477–482.
   PubMed Web of Science ®Google Scholar
• Kudelka AP, Verschraegen CF, Levy T, et al. Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs. 1996;7:398–401.
   PubMed Web of Science ®Google Scholar
• Hennenfent KL1, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol. 2006 May;17(5):735–749. Epub 2005 Dec 19.
   PubMed Web of Science ®Google Scholar
• Diéras V, Lortholary A, Laurence V, et al. Cabazitaxel in patients with advanced solid tumours: results of a phase I and pharmacokinetic study. Eur J Cancer. 2013 Jan;49(1):25–34. Epub 2012 Sep 10.
   PubMed Web of Science ®Google Scholar
• Eisenberger M, Hardy-Bessard A-C, Kim CS, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol. 2017 Oct 1;35(28):3198–3206. Epub 2017 Aug 15.
   PubMed Web of Science ®Google Scholar
• Benedetti-Panici P, Greggi S, Colombo A, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol. 2002 Jan 1;20(1):179–188. PubMed PMID: 11773168.
   PubMed Web of Science ®Google Scholar
• Mobus V. Adjuvant dose-dense chemotherapy in breast cancer: standard of care in high-risk patients. Breast Care (Basel). 2016 Feb;11(1):8–12. PubMed PMID: 27051389; PubMed Central PMCID: PMCPMC4813643.
   PubMed Web of Science ®Google Scholar
• Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003 Nov;39(17):2470–2486.
   PubMed Web of Science ®Google Scholar
• Lissoni AA, Colombo N, Pellegrino A, et al. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the snap-02 Italian collaborative study. Ann Oncol. 2009 Apr;20(4):660–665. PubMed PMID: 19181826.
   PubMed Web of Science ®Google Scholar
• Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist. 2001;6(Suppl 3):30–35. PubMed PMID: 11346683.
   PubMed Web of Science ®Google Scholar
• Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840. J Clin Oncol. 2008 Apr 1;26(10):1642–1649. PubMed PMID: 18375893.
   PubMed Web of Science ®Google Scholar
• Benedetti PP, Palaia I, Marchetti C, et al. Dose-dense neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer: a phase II study. Oncology. 2015;89(2):103–110. PubMed PMID: 25924602.
   PubMed Web of Science ®Google Scholar
• Zanaboni F, Grijuela B, Giudici S, et al. Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: results of a phase II multicentric study. Eur J Cancer. 2013 Mar;49(5):1065–1072. PubMed PMID: 23151423.
   PubMed Web of Science ®Google Scholar
• Leone B, Vallejo C, Perez J, et al. Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma. Am J Clin Oncol. 1996 Apr;19(2):132–135. PubMed PMID: 8610635.
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Distefano MG, De Vincenzo R, et al. Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results. Gynecol Oncol. 2013 Mar;128(3):518–523. PubMed PMID: 23237767.
   PubMed Web of Science ®Google Scholar
• Tambaro R, Scambia G, Di Maio M, et al. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. Crit Rev Oncol Hematol. 2004 Oct;52(1):33–44. PubMed PMID: 15363465.
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Lorusso D, et al. The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. Gynecol Oncol. 2019 Apr;9(153):535–540. PubMed PMID: 30979589.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Papadimitriou CA, Sarris K, et al. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the hellenic cooperative oncology group. Gynecol Oncol. 2002;85(3):476–482.
   PubMed Web of Science ®Google Scholar
• Buda A, Fossati R, Colombo N, et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian collaborative study. J Clin Oncol. 2005 Jun 20;23(18):4137–4145. PubMed PMID: 15961761.
   PubMed Web of Science ®Google Scholar
• Salihi R, Leunen K, Moerman P, et al. Neoadjuvant weekly paclitaxel-carboplatin is effective in stage I-II cervical cancer. Int J Gynecol Cancer. 2017 Jul;27(6):1256–1260. PubMed PMID: 28574931.
   PubMed Web of Science ®Google Scholar
• Tanioka M, Yamaguchi S, Shimada M, et al. Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study. Med Oncol. 2017 Aug;34(8):134. PubMed PMID: 28681218.
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Corrado G, Vitrano G, et al. Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study. Cancer Chemother Pharmacol. 2019 Mar;83(3):431–438. PubMed PMID: 30506402.
   PubMed Web of Science ®Google Scholar
• Tinker AV, Bhagat K, Swenerton KD, et al. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia cancer agency experience. Gynecol Oncol. 2005 Jul;98(1):54–58. PubMed PMID: 15904950.
   PubMed Web of Science ®Google Scholar
• Thigpen T, Vance R, Khansur T, et al. The role of paclitaxel in the management of patients with carcinoma of the cervix. Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-41-S2-46. PubMed PMID: 9045336.
   PubMed Web of Science ®Google Scholar
• Bonomi P, Blessing JA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 1985 Aug;3(8):1079–1085. PubMed PMID: 3894589.
   PubMed Web of Science ®Google Scholar
• Sutton GP, Blessing JA, McGuire WP, et al. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a gynecologic oncology group study. Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):805–807. PubMed PMID: 8456884.
   PubMed Web of Science ®Google Scholar
• Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in squamous cell carcinoma of the cervix: A phase II study of the gynecologic oncology group. Gynecol Oncol. 2000 Jun;77(3):446–449. PubMed PMID: 10831357.
   PubMed Web of Science ®Google Scholar
• Mclachlan, McLachlan J, Boussios S, et al. The impact of systemic therapy beyond first-line treatment for advanced cervical cancer. R Coll Radiol. 2017 Mar;29(3):153–160.
   PubMed Web of Science ®Google Scholar
• Tanioka M, Katsumata N, Yonemor IK, et al. Second platinum- therapy in patients with uterine cervical cancer. Cancer Che- Mother Pharmacol. 2011;68:337e342.
   Web of Science ®Google Scholar
• Takekuma M, Kuji S, Tanaka A, et al. Platinum-sensitivity and non-cross resistance of cisplatin analogue with cisplatin in recurrent cervical cancer. J Gynecol Oncol. 2015;26:185e192.
   Web of Science ®Google Scholar
• McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. A gynecologic oncology group study. J Clin Oncol. 1996 Mar;14(3):792–795. PubMed PMID: 8622025.
   PubMed Web of Science ®Google Scholar
• Thigpen T, Shingleton H, Homesley H, et al. cis-dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the gynecologic oncology group. Cancer Treat Rep. 1979 Sep-Oct;63(9–10):1549–1555. PubMed PMID: 498154.
   PubMedGoogle Scholar
• Pectasides D, Kamposioras K, Papaxoinis G, et al. Chemotherapy for recurrent cervical cancer. Cancer Treat Rev. 2008 Nov;34(7):603–613. PubMed PMID: 18657909.
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Gershenson DM, et al. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 1999 Sep;17(9):2676–2680. PubMed PMID: 10561341.
   PubMed Web of Science ®Google Scholar
• Pignata S, Silvestro G, Ferrari E, et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol. 1999 Mar;17(3):756–760. PubMed PMID: 10071263.
   PubMed Web of Science ®Google Scholar
• Fiorica J, Holloway R, Ndubisi B, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 2002 Apr;85(1):89–94. PubMed PMID: 11925125.
   PubMed Web of Science ®Google Scholar
• Davidson S. Treatment for advanced cervical cancer: impact on quality of life. Crit Rev Oncol Hematol. 2011 Jul;79(1):24–30. . PubMed PMID: 20810289.
   PubMed Web of Science ®Google Scholar
• McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol. 1996 Mar;14(3):792-795.
   Google Scholar
• Papadimitriou CA, Sarris K, Moulopoulos LA, et al. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol. 1999 Mar;17(3):761–766. PubMed PMID: 10071264.
   PubMed Web of Science ®Google Scholar
• Moore DH. Chemotherapy for recurrent cervical carcinoma. Curr Opin Oncol. 2006 Sep;18(5):516–519. . PubMed PMID: 16894302.
   PubMed Web of Science ®Google Scholar
• Fracasso PM, Blessing JA, Wolf J, et al. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2003 Jul;90(1):177–180. PubMed PMID: 12821360.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol. 2009 Oct 1;27(28):4649–4655. PubMed PMID: 19720909; PubMed Central PMCID: PMCPMC2754911.
   PubMed Web of Science ®Google Scholar
• Tsuda N, Watari H, Ushijima K. Chemotherapy and molecular targeting therapy for recurrent cervical cancer. Chin J Cancer Res. 2016 Apr;28(2):241–253. . PMID: 27199523.
   PubMed Web of Science ®Google Scholar
• Lorusso D, Ramondino S, Mancini M, et al. Phase II trial on cisplatin-adriamycin-paclitaxel combination as neoadjuvant chemotherapy for locally advanced cervical adenocarcinoma. International Journal of Gynecologic Cancer. 2014;24(4):729-734.
   Google Scholar
• Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007 May;105(2):299–303. PubMed PMID: 17303230.
   PubMed Web of Science ®Google Scholar
• Kitagawa R, Katsumata N, Shibata T, et al. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan clinical oncology group study (JCOG0505). J Clin Oncol. 2012;30(15_suppl):5006.
   Web of Science ®Google Scholar
• Garces AH, Mora PA, Alves FV, et al. First-line paclitaxel and carboplatin in persistent/recurrent or advanced cervical cancer: a retrospective analysis of patients treated at Brazilian national cancer institute. Int J Gynecol Cancer. 2013 May;23(4):743–748. PubMed PMID: 23552805.
   PubMed Web of Science ®Google Scholar
• Choi CH, Kim TJ, Lee SJ, et al. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer. 2006 May-Jun;16(3):1157–1164. PubMed PMID: 16803500.
   PubMed Web of Science ®Google Scholar
• Takekuma M, Hirashima Y, Ito K, et al. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a kansai Clinical Oncology Group study. Gynecol Oncol. 2012 Sep;126(3):341–345. PubMed PMID: 22609108.
   PubMed Web of Science ®Google Scholar
• Barra F, Lorusso D, Leone Roberti Maggiore U, et al. Investigational drugs for the treatment of cervical cancer. Expert Opin Investig Drugs. 2017 Apr;26(4):389–402. PubMed PMID: 28274154; eng.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009 Mar 1;27(7):1069–1074. PubMed PMID: 19139430; PubMed Central PMCID: PMCPMC2667811.
   PubMed Web of Science ®Google Scholar
• Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013 Jul;130(1):64–68. PubMed PMID: 23591400; PubMed Central PMCID: PMCPMC3870479.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJ 3rd. et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20;370(8):734–743. PubMed PMID: 24552320; PubMed Central PMCID: PMCPMC4010094. Eng.
   PubMed Web of Science ®Google Scholar
• Paul Symonds R, Gourley C, Davidson S, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2015;16:1515–1524.
   PubMed Web of Science ®Google Scholar
• Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010 [Cited 2010 Mar 04];10(4):293–301. en.
   PubMed Web of Science ®Google Scholar
• Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis. 1999 Feb;20(2):199–203. PubMed PMID: 10069454; Eng.
   PubMed Web of Science ®Google Scholar
• A limited access phase I trial of paclitaxel, cisplatin and ABT-888 in the treatment of advanced, persistent, or recurrent carcinoma of the cervix: an NRG/GOG study. 2015 ASCO Annual Meeting | Abstracts | Meeting Library 2016. Available from: http://meetinglibrary.asco.org/content/148460-156
   Google Scholar
• Minion LE, Tewariexpand KS. Cervical cancer - state of the science: from angiogenesis blockade to checkpoint inhibition. Gynecol Oncol. 2018 Mar;148(3):609–621. PMID: 29666026.
   PubMed Web of Science ®Google Scholar
• Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008 Jul 1;14(13):4200–4205. PubMed PMID: 18594000; PubMed Central PMCID: PMCPMC2661025.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006 Feb 15;12(4):1317–1324. PubMed PMID: 16489089.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009 Aug 1;27(22):3611–3619. PubMed PMID: 19470941.
   PubMed Web of Science ®Google Scholar
• Chen TT, Ng TH. Optimal flexible designs in phase II clinical trials. Stat Med. 1998 Oct 30;17(20):2301–2312. PubMed PMID: 9819829.
   PubMed Web of Science ®Google Scholar
• Paik PK, James LP, Riely GJ, et al. A phase 2 study of weekly albumin-bound paclitaxel (Abraxane(R)) given as a two-hour infusion. Cancer Chemother Pharmacol. 2011 Nov;68(5):1331–1337. PubMed PMID: 21461889; PubMed Central PMCID: PMCPMC3581346.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Blessing JA, Landrum LM, et al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol. 2012 Dec;127(3):451–455. PubMed PMID: 22986144; PubMed Central PMCID: PMCPMC4459779.
   PubMed Web of Science ®Google Scholar
• Minion LE, Chase DM, Farley JH, et al. Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study. Gynecol Oncol Res Pract. 2016;3:4. . PubMed PMID: 27231575; PubMed Central PMCID: PMCPMC4880945.
   PubMedGoogle Scholar
• Kim J, Bae SM, Lim DS, et al. Tetraarsenic oxide-mediated apoptosis in a cervical cancer cell line, SiHa. Cancer Res Treat. 2005 Oct;37(5):307–312. PubMed PMID: 19956532; PubMed Central PMCID: PMCPMC2785923.
   PubMedGoogle Scholar
• MM W. Clinical Hematology. Vol. 1. 3rd ed. London: Lippincott Williams & Wilkins; 1951.
   Google Scholar
• Byun JM, Jeong DH, Lee DS, et al. Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer. Oncol Rep. 2013 Apr;29(4):1540–1546. PubMed PMID: 23338680.
   PubMed Web of Science ®Google Scholar
• Pennati M, Campbell AJ, Curto M, et al. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328–1337. PubMed PMID: 16170024.
   PubMed Web of Science ®Google Scholar
• Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol. 1999 Apr 16;287(5):821–828. PubMed PMID: 10222191.
   PubMed Web of Science ®Google Scholar
• Gu F, Li L, Yuan QF, et al. Down-regulation of survivin enhances paclitaxel-induced hela cell apoptosis. Eur Rev Med Pharmacol Sci. 2017 Aug;21(15):3504–3509. PubMed PMID: 28829489.
   PubMed Web of Science ®Google Scholar
• Xi C, Wang L, Yu J, et al. Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer. Biochem Biophys Res Commun. 2019 Apr;10(513):589–593. PubMed PMID: 30979499.
   PubMed Web of Science ®Google Scholar
• Cox Gad S. Development of Therapeutic agents handbook. Hoboken, NJ: John Wiley & Sons; 2011.
   Google Scholar
• Barra F, Evangelisti G, Damiano G, et al. New perspectives with targeted drugs. Ferrero S, editor. Nova science publisher; 2018. Endometrial Cancer: Risk factors MaP, editor.
   Google Scholar
• Bizzarri N, Ghirardi V, Alessandri F, et al. Bevacizumab for the treatment of cervical cancer. Expert Opin Biol Ther. 2016;16(3):407–419.
   PubMed Web of Science ®Google Scholar
• Barra F, Lagana AS, Ghezzi F, et al. Nintedanib for advanced epithelial ovarian cancer: a change of perspective? summary of evidence from a systematic review. Gynecol Obstet Invest. 2018 Oct 10:1–11. PubMed PMID: 30304728. DOI:10.1159/000493361
   PubMed Web of Science ®Google Scholar
• Tantari M, Barra F, Di Domenico S, et al. Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas. Expert Opin Pharmacother. 2019 Apr;20(6):713–723. PubMed PMID: 30724615.
   PubMed Web of Science ®Google Scholar
• Barra F, Evangelisti G, Ferro DL, et al. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs. 2019 Feb;28(2):131–142. PubMed PMID: 30574817.
   PubMed Web of Science ®Google Scholar